Orchard Therapeutics plc
ORTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -13.8% | 491.3% | -82.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 72.3% | 70.1% | 70.3% | 127.3% |
| R&D Expenses | $0 | $0 | $0 | -$0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | -$0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -342.8% | -308.5% | -2,122.7% | 1,904.9% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -560.4% | -168.3% | -1,407.6% | 1,930.9% |
| EPS | -1.55 | -0.65 | -1.23 | 10.52 |
| % Growth | -138.5% | 47.2% | -111.7% | – |
| EPS Diluted | -1.55 | -0.65 | -1.23 | 10.52 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -549.4% | -266.8% | -1,590.6% | 1,915.2% |